Patent details

EP2841437 Title: IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION

Basic Information

Publication number:
EP2841437
PCT Application Number:
US2013037956
Type:
European Patent Granted for LU
Legal Status:
In force
Application number:
EP137218574
PCT Publication Number:
WO2013163279
First applicant's nationality:
Translation Language:
EPO Publication Language:
English
English Title of Invention:
IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION
French Title of Invention:
DÉRIVÉS D'IMIDAZOTHIADIAZOLE ET D'IMIDAZOPYRAZINE UTILISÉS COMME INHIBITEURS DU RÉCEPTEUR 4 ACTIVÉ PAR UNE PROTÉASE (PAR4) POUR LE TRAITEMENT DE L'AGRÉGATION PLAQUETTAIRE
German Title of Invention:
IMIDAZOTHIADIAZOL- UND IMIDAZOPYRAZINDERIVATE ALS PROTEASEAKTIVIERTE REZEPTOR 4 (PAR4)-INHIBITOREN ZUR BEHANDLUNG VON THROMBOZYTENAGGREGATION
SPC Number:

Dates

Filing date:
24/04/2013
Grant date:
05/07/2017
EP Publication Date:
04/03/2015
PCT Publication Date:
31/10/2013
Claims Translation Received Date:
Translations Received Date (B1 EP Publication):
Translations Received Date (B2 EP Publication):
Translations Received Date (B3 EP Publication):
Publication date:
05/07/2017
EP B1 Publication Date:
05/07/2017
EP B2 Publication Date:
EP B3 Publication Date:
Lapsed date:
Expiration date:
24/04/2033
Renunciation date:
Revocation date:
Annulment date:

Owner

From:
05/07/2017
 
 

Name:
Bristol-Myers Squibb Company
Address:
Route 206 and Province Line Road, Princeton, NJ 08543, United States (US)

Name:
Université de Montréal
Address:
2900 Boulevard Edouard-Montpetit, Montreal, QC H3T 1J4, Canada (CA)

Agent

1

Name:
MARKS & CLERK LLP
From:
12/08/2022
Address:
BP 1775, 1017, LUXEMBOURG, Luxembourg (LU)
To:

2

Name:
MARKS & CLERK LLP
From:
25/07/2017
Address:
B.P. 1775, 1017, LUXEMBOURG, Luxembourg (LU)
To:
12/08/2022

Inventor

1

Name:
PRIESTLEY, Eldon Scott
Address:
United States (US)

2

Name:
MAXWELL, Brad D.
Address:
United States (US)

3

Name:
RUEDIGER, Edward H.
Address:
Canada (CA)

4

Name:
POSY, Shoshana L.
Address:
United States (US)

5

Name:
BANVILLE, Jacques
Address:
Canada (CA)

6

Name:
DUBÉ, Laurence
Address:
Canada (CA)

7

Name:
GUY, Julia
Address:
Canada (CA)

8

Name:
RÉMILLARD, Roger
Address:
Canada (CA)

9

Name:
GAGNON, Marc
Address:
Canada (CA)

10

Name:
LAWRENCE, Michael, R.
Address:
United States (US)

11

Name:
WONG, Pancras C.
Address:
United States (US)

12

Name:
DEON, Daniel H.
Address:
Canada (CA)

13

Name:
MILLER, Michael, M.
Address:
United States (US)

Priority

1

Priority Number:
201261638577 P
Priority Date:
26/04/2012
Priority Country:
United States (US)

2

Priority Number:
201361787680 P
Priority Date:
15/03/2013
Priority Country:
United States (US)

Classification

IPC classification:
A61K 31/433; A61K 31/4355; A61K 31/5025; A61P 7/02; C07D 487/04; C07D 513/04; C07D 519/00;

Publication

European Patent Bulletin

Issue number:
201727
Publication date:
05/07/2017
Description:
Grant (B1)

Annual Fees

Annual Fee Due Date:
31/10/2025
Annual Fee Number:
13
Annual Fee Amount:
180 Euro
Penalty Fee Amount:
20 Euro
Expected Payer:
Last Annual Fee Payment Date:
11/04/2024
Last Annual Fee Paid Number:
12
Last Annual Fee Paid Amount:
165 Euro
Payer:
CPA GLOBAL THE IP PLATFORM
Filing date Document type Number of pages
03/08/2017 Outgoing Correspondence 1
25/07/2017 Power Of Attorney 1
12/08/2022 Request For Change 1
02/09/2022 Outgoing Correspondence 56